| Hazard Information | Back Directory | [Uses]
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma[1][2][3]. | [in vivo]
Anrukinzumab (IMA-638; 10 mg/kg; intravenous infusion; single) reduces lung inflammation in cynomolgus monkey model of lung inflammation[1]. | Animal Model: | Adult male cynomolgus monkeys (6 to 10 kg; cynomolgus monkey model of lung inflammation)[1]. | | Dosage: | 10 mg/kg | | Administration: | Intravenous infusion; single | | Result: | Reduced total BAL cell count, eosinophil number, and neutrophil number.
Reduced the levels of eotaxin and RANTES in BAL fluid.
|
| [References]
[1] Bree A, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007 May;119(5):1251-7. DOI:10.1016/j.jaci.2007.02.009
[2] Reinisch W, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut. 2015 Jun;64(6):894-900. DOI:10.1136/gutjnl-2014-308337
[3] Elias JA, et al. IL-13 in asthma. The successful integration of lessons from mice and humans. Am J Respir Crit Care Med. 2011 Apr 15;183(8):957-8. DOI:10.1164/rccm.201101-0080ED |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|